Compare · ARGX vs CLDI
ARGX vs CLDI
Side-by-side comparison of argenx SE (ARGX) and Calidi Biotherapeutics Inc. (CLDI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and CLDI operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.41B, about 23259.9x CLDI ($2.3M).
- Over the past year, ARGX is up 52.5% and CLDI is down 98.3% - ARGX leads by 150.8 points.
- CLDI has been more active in the news (6 items in the past 4 weeks vs 3 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 2 for CLDI).
- Company
- argenx SE
- Calidi Biotherapeutics Inc.
- Price
- $861.30+0.30%
- $0.12+3.62%
- Market cap
- $53.41B
- $2.3M
- 1M return
- -1.91%
- -23.29%
- 1Y return
- +52.49%
- -98.33%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- AMEX
- IPO
- 2017
- 2021
- News (4w)
- 3
- 6
- Recent ratings
- 25
- 2
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Latest CLDI
- Calidi Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
- SEC Form 3 filed by new insider Sanders Corazon (Corsee) D.
- Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
- Calidi Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
- Calidi Biotherapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
- Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026
- SEC Form DEFA14A filed by Calidi Biotherapeutics Inc.